• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Rectogesic
    / Perrigo


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Ointment

    30 gr

    not in the basket chart 83584 18414

    Dosage

    Route of administration: rectal use
    Adults: A finger covering, such as cling film or a finger cot, may be placed on the finger to be used to apply the ointment. (Finger cots to be obtained separately from local pharmacy or surgical supplies retailer or cling film from local store.) The finger is placed along side a 2.5cm dosing line which is provided on the outside carton in which Rectogesic is supplied, and a strip of ointment the length of the line is expressed onto the end of the finger by gently squeezing the
    tube. The amount of ointment expressed is approximately 375 mg (1.5 mg GTN). The covered finger is then gently inserted into the anal canal to the distal interphalangeal joint of the finger and applied circumferentially to the anal canal.
    The dose delivered from the 4 mg/g ointment is 1.5 mg glyceryl trinitrate. The dose is to be applied intra-anally every twelve hours. Treatment may be continued until the pain abates, up to a maximum of 8 weeks.
    Rectogesic should be used following conservative treatment failure for acute symptoms of anal fissure.
    Elderly (over 65 years): No specific information concerning the usage of Rectogesic in the elderly is available.
    Patients with Hepatic or Renal Impairment: No specific information concerning the usage of Rectogesic in patients with hepatic or renal impairment is available.
    Children and Adolescents: Rectogesic is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy.


    Indications

    Relief of pain associated with chronic anal fissure.


    Contra-Indications

    Hypersensitivity to the glyceryl trinitrate or to any of the excipients or idiosyncratic reactions to other organic nitrates. Concomitant treatment with sildenafil citrate, tadalafil, vardenafil and with nitric oxide donors, such as other long-acting GTN products, isosorbide dinitrate and amyl or butyl-nitrite. Postural hypotension, hypotension or uncorrected hypovolemia as the use of glyceryl trinitrate in such states could produce severe hypotension or shock. Increased intracranial pressure (e.g. head trauma or cerebral hemorrhage) or inadequate cerebral circulation. Migraine or recurrent headache. Aortic or mitral stenosis. Hypertrophic obstructive cardiomyopathy. Constrictive pericarditis or pericardial tamponade. Marked anaemia. Closed-angle glaucoma.


    Drug interactions

    Sildenafil citrate, tadalafil, vardenafil and with nitric oxide donors, such as other long-acting GTN products, isosorbide dinitrate and amyl or butyl-nitrite.


    Manufacturer
    Phabril Waltrop GmbH
    CLOSE